China Pharma Holdings, Inc. (CPHI) AI Stock Analysis

China Pharma Holdings, Inc. develops, manufactures, and distributes generic and branded pharmaceutical and biochemical products in the People's Republic of China. Catering primarily to hospitals and private retailers, its portfolio spans dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. These products target conditions such as memory decline, attention deficit, coronary heart disease, hypertension, tonsillitis, and digestive disorders, featuring offerings like Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole. Founded in 1993, the company operates 16 sales offices and deploys approximately 1,000 sales representatives across the region.

CPHI has faced steady top-line pressure, with revenue decreasing from $9.6M in FY2021 to $8.1M in FY2022, $7.0M in FY2023, $4.5M in FY2024, and $4.1M in FY2025, representing a 5-year revenue CAGR of -17.5%. Gross margin remained negative across four of the last five years, registering at -3.2% in FY2025 compared to -43.8% in FY2024. Operating margin stood at -74.5% in FY2025, and annual net income was -$3.2M, reflecting a net margin of -76.9%. For the latest quarter ending June 30, 2026, quarterly revenue growth contracted 7.5% year-over-year, while trailing twelve months revenue reached $3.9M with an operating margin of -151.0%.

As of June 30, 2026, China Pharma Holdings held $304,874 in cash and short-term investments alongside total debt of $3.8M, yielding net debt of $3.4M and total assets of $44.7M. The balance sheet indicates tight liquidity with a current ratio of 0.26, while debt-to-equity stood at 0.10 against shareholders' equity of $36.2M. Cash flow generation showed a modest turnaround in FY2025, with operating cash flow reaching $148,261 and free cash flow totaling $11,010. During FY2025, capital expenditures were $137,251, while share count contracted 10.2% over five years.

Trading at $0.71 as of October 16, 2026, CPHI has a market capitalization of $30.5M and an enterprise value of $34.7M. The stock trades at a price-to-sales multiple of 7.8x and an enterprise value-to-revenue multiple of 8.9x, compared to the median of 4.1x price-to-sales for its US-listed Healthcare peers. Its forward price-to-earnings ratio is 1.6x versus the peer median of 17.3x, alongside a price-to-book multiple of 0.9x. Over the past year, CPHI fell 62.2% while the S&P 500 gained 16.8%; over five years, the stock dropped 99.7% against an 83.0% gain for the benchmark.

Wall Street coverage on CPHI features a mean price target of $3.00, representing an upside of 322.5% compared to the October 16, 2026 closing price of $0.71. Across its recent reporting periods, the company recorded 0 EPS beats over the last 4 quarters. The next earnings date for China Pharma Holdings is scheduled for November 11, 2026.

This page is an AI-written research summary of China Pharma Holdings, Inc. (CPHI). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: CPHI income statement, CPHI balance sheet, CPHI key metrics, CPHI chart. See the CPHI stock overview for the latest quote and news.